{"id":"phase-2-amisulpride","safety":{"commonSideEffects":[{"rate":null,"effect":"Elevated prolactin levels"},{"rate":null,"effect":"Amenorrhea"},{"rate":null,"effect":"Galactorrhea"},{"rate":null,"effect":"Sexual dysfunction"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Anxiety"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amisulpride preferentially blocks dopamine receptors in the mesolimbic and mesocortical pathways at low doses, producing antipsychotic and antidepressant effects. At higher doses, it also blocks dopamine in the nigrostriatal pathway. Unlike typical antipsychotics, amisulpride has minimal affinity for other neurotransmitter receptors, resulting in a favorable side effect profile.","oneSentence":"Amisulpride is a selective dopamine D2 and D3 receptor antagonist that blocks dopamine signaling in the brain to reduce psychotic symptoms and improve mood.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:12.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Psychotic disorders"},{"name":"Major depressive disorder with psychotic features"}]},"trialDetails":[{"nctId":"NCT02926859","phase":"PHASE2","title":"Enhancing Recovery in Early Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2017-04-08","conditions":"Schizophrenia","enrollment":180},{"nctId":"NCT05546359","phase":"PHASE2, PHASE3","title":"Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2024-01-18","conditions":"Nausea and Vomiting, Postoperative","enrollment":453},{"nctId":"NCT03510325","phase":"PHASE3","title":"Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2019-02-12","conditions":"Schizophrenia","enrollment":762},{"nctId":"NCT05822713","phase":"PHASE3","title":"A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV.","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical (Hainan) Co., Ltd.","startDate":"2023-04-29","conditions":"PONV","enrollment":516},{"nctId":"NCT03451734","phase":"","title":"Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients","status":"COMPLETED","sponsor":"Central South University","startDate":"2018-01-23","conditions":"Schizophrenia, Metabolic Syndrome","enrollment":2000},{"nctId":"NCT01857232","phase":"PHASE2","title":"Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy","status":"COMPLETED","sponsor":"Acacia Pharma Ltd","startDate":"2013-10","conditions":"CINV","enrollment":342},{"nctId":"NCT01248195","phase":"PHASE4","title":"Optimization of Treatment and Management of Schizophrenia in Europe","status":"COMPLETED","sponsor":"Rene Kahn","startDate":"2011-05","conditions":"Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder","enrollment":479},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":"Psychosis Nos/Other","enrollment":104},{"nctId":"NCT00534573","phase":"PHASE3","title":"Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation","status":"COMPLETED","sponsor":"Beersheva Mental Health Center","startDate":"2008-11","conditions":"Clozapine-induced Hypersalivation","enrollment":54},{"nctId":"NCT01105481","phase":"PHASE4","title":"Amisulpride Augmentation Therapy for Clozapine-resistant Schizophrenic Patients","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2006-05","conditions":"Treatment-resistant Schizophrenia","enrollment":273}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":75,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Phase 2: Amisulpride","genericName":"Phase 2: Amisulpride","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amisulpride is a selective dopamine D2 and D3 receptor antagonist that blocks dopamine signaling in the brain to reduce psychotic symptoms and improve mood. Used for Schizophrenia, Psychotic disorders, Major depressive disorder with psychotic features.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}